Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Basit Öğe Kaydı
dc.authorid0000-0002-7071-2471
dc.authorid0000-0002-8417-8628
dc.contributor.authorKılıçkap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGümüş, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.date.accessioned2025-05-10T19:27:50Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.endpageS101
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3
dc.identifier.scopusqualityQ1
dc.identifier.startpageS101
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7072
dc.identifier.volume16
dc.identifier.wosWOS:000631349600072
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectnon-small cell lung cancer
dc.subjectanti-PD-1
dc.subjectcemiplimab
dc.titleClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu